Literature DB >> 16886910

Review article: management of hepatic disease following haematopoietic cell transplant.

G B McDonald1.   

Abstract

Hepatic diseases are common complications of haematopoietic cell transplant. The causes are multiple: myeloablative conditioning regimens may cause sinusoidal injury; acute and chronic graft-versus-host disease lead to damaged hepatocytes and small bile ducts; microcrystalline deposits in the gall bladder can cause biliary symptoms; drug-induced liver injury is common; and the liver may be infected by viruses and fungi during the period of severe immune suppression that follows transplant. Pre-transplant evaluation and prevention of liver injury are often more useful than treatment of deeply jaundiced patients in improving transplant outcomes. This review covers pre-transplant evaluation, common hepatobiliary problems in the six months following transplant, and hepatic problems in long-term survivors.

Entities:  

Mesh:

Year:  2006        PMID: 16886910     DOI: 10.1111/j.1365-2036.2006.03001.x

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  9 in total

1.  Personalized dosing of cyclophosphamide in the total body irradiation-cyclophosphamide conditioning regimen: a phase II trial in patients with hematologic malignancy.

Authors:  J S McCune; A Batchelder; K A Guthrie; R Witherspoon; F R Appelbaum; B Phillips; P Vicini; D H Salinger; G B McDonald
Journal:  Clin Pharmacol Ther       Date:  2009-03-18       Impact factor: 6.875

2.  Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective.

Authors:  Marcie Tomblyn; Tom Chiller; Hermann Einsele; Ronald Gress; Kent Sepkowitz; Jan Storek; John R Wingard; Jo-Anne H Young; Michael J Boeckh; Michael A Boeckh
Journal:  Biol Blood Marrow Transplant       Date:  2009-10       Impact factor: 5.742

3.  Prognostic significance of liver parameters at 1-year follow-up in children and adults undergoing myeloablative allogeneic stem cell transplantation.

Authors:  K Jordan; I J Christensen; M H Jørgensen; C Heilmann; H Sengeløv; K G Müller
Journal:  Bone Marrow Transplant       Date:  2015-03-23       Impact factor: 5.483

4.  Kinetics of iron removal by phlebotomy in patients with iron overload after allogeneic hematopoietic cell transplantation.

Authors:  Ann-Kathrin Eisfeld; Rainer Krahl; Nadja Jaekel; Dietger Niederwieser; Haifa Kathrin Al-Ali
Journal:  Am J Blood Res       Date:  2012-11-25

5.  Iron overload in patients undergoing hematopoietic stem cell transplantation.

Authors:  Vinod Pullarkat
Journal:  Adv Hematol       Date:  2010-09-08

6.  Efficacy and safety of deferasirox in non-thalassemic patients with elevated ferritin levels after allogeneic hematopoietic stem cell transplantation.

Authors:  N Jaekel; K Lieder; S Albrecht; O Leismann; K Hubert; G Bug; N Kröger; U Platzbecker; M Stadler; K de Haas; S Altamura; M U Muckenthaler; D Niederwieser; H K Al-Ali
Journal:  Bone Marrow Transplant       Date:  2015-09-14       Impact factor: 5.483

7.  Severe hepatocellular injury after hematopoietic cell transplant: incidence, etiology and outcome.

Authors:  M Sakai; S I Strasser; H M Shulman; S J McDonald; H G Schoch; G B McDonald
Journal:  Bone Marrow Transplant       Date:  2009-03-23       Impact factor: 5.483

8.  Profile of Hepatobiliary Dysfunction in Hematopoietic Stem Cell Transplant Recipients - An Indian Perspective.

Authors:  Manish Manrai; Emil George; Rajan Kapoor
Journal:  J Clin Exp Hepatol       Date:  2020-07-02

Review 9.  Acute graft versus host disease.

Authors:  David A Jacobsohn; Georgia B Vogelsang
Journal:  Orphanet J Rare Dis       Date:  2007-09-04       Impact factor: 4.123

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.